OncoMatch/Clinical Trials/NCT06693323
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Is NCT06693323 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies AHCC®capsules for hnscc.
Treatment: AHCC®capsules — This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HPV positive
diagnosis of pathologically or cytologically proven HPV positive HNSCC
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500/μL; Platelets ≥ 100,000/μL
Kidney function
Creatinine clearance > 30 mL/min using the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); AST or /ALT ≤ 3.0 × institutional ULN
Has adequate organ and marrow function as defined below, based on clinical laboratory assessments obtained ≤ 28 days prior to registration: 1. Absolute neutrophil count (ANC) ≥ 1,500/μL 2. Platelets ≥ 100,000/μL 3. Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) 4. AST or /ALT ≤ 3.0 × institutional ULN 5. Creatinine clearance > 30 mL/min using the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify